AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00002064
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04846036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of matching placebo twice daily
Trial: NCT05411809
Drug: drug adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
Trial: NCT02987257
Drug: Harmonized supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harmonized supportive care with and etanercept placebo days 1 and 4
Trial: NCT02701023
Drug: MitoGel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
Trial: NCT06227910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib matched placebo capsules.
Trial: NCT05010668
Drug: cryoablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoablation treatment starts at day 0.
Trial: NCT05295732
Drug: TMB-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TMB-001 0.05% QD/BID
Trial: NCT05295732
Drug: Matching Vehicle
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Vehicle
Trial: NCT05665881
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vasopressor
Trial: NCT05206773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT05184452
Drug: PGDM1400LS (20mg/kg, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg to be administered via IV infusion
Trial: NCT05184452
Drug: PGDM1400LS (40mg/kg, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg to be administered via IV infusion
Trial: NCT05184452
Drug: PGDM1400LS (1.4g, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4gram to be administered via IV infusion
Trial: NCT05184452
Drug: PGDM1400LS (1.4g, SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4gram to be administered via SC infusion
Trial: NCT05184452
Drug: VRC07-523LS (20mg/kg, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS 20mg/kg administered via IV infusion
Trial: NCT05184452
Drug: VRC07-523LS (20mg/kg, SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS 20mg/kg administered via SC infusion
Trial: NCT05184452
Drug: VRC07-523LS (1.4g, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS 1.4g administered via IV infusion
Trial: NCT05184452
Drug: VRC07-523LS (1.4g, SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS 1.4g administered via SC infusion
Trial: NCT05184452
Drug: VRC07-523LS (40mg/kg, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS 40mg/kg administered via IV infusion
Trial: NCT05184452
Drug: PGT121.414.LS (20mg/kg, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 20mg/kg administered via IV infusion
Trial: NCT05184452
Drug: PGT121.414.LS (1.4g, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 1.4g administered via IV infusion
Trial: NCT05184452
Drug: PGT121.414.LS (40mg/kg, IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 40mg/kg administered via IV infusion
Trial: NCT04275531
Drug: Anesthesia Agent
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: various anesthetic agents used in both general and regional anesthesia
Trial: NCT05247255
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL block with saline
Trial: NCT05453500
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05453500
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06505148
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered alternatively with other drug
Trial: NCT06505148
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered alternatively with other drug
Trial: NCT05285085
Drug: Statin
RxNorm normalized name: Statin
DrugBank: Apstatin (DB04092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin use
Trial: NCT04782661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be administered orally.
Trial: NCT05262179
Drug: CTO0101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop/ once or three times a day/ for 17 days divided into stage2
Trial: NCT05766670
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
Trial: NCT05177094
Drug: LY3526318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05177094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00608816
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
Trial: NCT00608816
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
Trial: NCT06244992
Drug: PTT-936
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).
Trial: NCT06244992
Drug: Combination of PTT-936 and anti-PD-1/L1 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).
Trial: NCT06263959
Drug: Placebo to match GST-HG131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GST-HG131 will be administered.
Trial: NCT05768932
Drug: BAL0891
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
Trial: NCT05981040
Drug: ZYIL1 capsules 25 mg and 50 mg Placebo
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
Trial: NCT05981040
Drug: ZYIL1 capsules 50 mg and 25 mg Placebo
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
Trial: NCT05981040
Drug: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
Trial: NCT05981040
Drug: Matching placebo 25 mg and Matching placebo 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
Trial: NCT04862234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
Trial: NCT05757102
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC/VI will be administered.
Trial: NCT06292013
Drug: Lepodisiran Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06292013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05100095
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
Trial: NCT04455841
Drug: INCB000928
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB000928 will be administered at protocol defined dose.
Trial: NCT05104463
Drug: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
Trial: NCT04570956
Drug: Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
Trial: NCT04570956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill or placebo gel
Trial: NCT06178055
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
Trial: NCT05316922
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
Trial: NCT06312345
Drug: Drug: ciprofol injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
Trial: NCT05498675
Drug: ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.
Trial: NCT05834777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride will be administered as the same rate as icatibant
Trial: NCT05526196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried flower cigarette with both placebo tobacco and cannabis
Trial: NCT05716763
Drug: Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg (20 drops) single dose
Trial: NCT05300035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria.
Trial: NCT05015192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, orally
Trial: NCT05025865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo will be given in capsule form to study participants.
Trial: NCT06647862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06199089
Drug: CM313 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment.
Trial: NCT05061550
Drug: AZD0171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD0171 via intravenous route.
Trial: NCT05960526
Drug: extract Binahong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract Binahong 2.5% as nasal irrigation solution
Trial: NCT05960526
Drug: Isotonic saline nasal irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% as nasal irrigation solution
Trial: NCT05198050
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tables with a similar appearance to letrozole
Trial: NCT04650490
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of immunotherapy per standard of care
Trial: NCT06049953
Drug: Antipsychotics
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
Trial: NCT05030818
Drug: Polypill of acetylsalicylic acid, ramipril and atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
Trial: NCT06049953
Drug: Non-antipsychotic medication
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
Trial: NCT05030818
Drug: Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
Trial: NCT06222749
Drug: Intranasal placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray solution; Placebo will be administered as the placebo controlled condition.
Trial: NCT06311786
Drug: [14C]-BIIB091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT06015659
Drug: Zentalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
Trial: NCT06437496
Drug: 68Ga-PSMA-11//68Ga-PSMA-617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
Trial: NCT05046353
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory remediation +/-D-serine
Trial: NCT05169554
Drug: Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
Trial: NCT06192277
Drug: Standard dose Penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
Trial: NCT04784715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT04784715
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
Trial: NCT04857502
Drug: 99mTc-based PSMA Imaging and Surgery Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given via IV injection
Trial: NCT05948579
Drug: Intervention B Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
Trial: NCT00257374
Drug: Gatorade, Pedialyte and New Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05197556
Drug: HSG4112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT05197556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT05265806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
Trial: NCT05915702
Drug: Gadoquatrane (BAY1747846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Trial: NCT04850937
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
Trial: NCT06414954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets taken twice a day for 21 days
Trial: NCT04989946
Drug: FLT PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
Trial: NCT06576037
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein (IV)
Trial: NCT06572397
Drug: H-1337 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT05426395
Drug: Vitamin B12 2.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).
Trial: NCT05426395
Drug: Vitamin B12 50 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
Trial: NCT06462235
Drug: Part A: ATM-AVI Single Dose, Cohorts 1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.
Trial: NCT06462235
Drug: Part B: Multiple-dose ATM-AVI, Cohorts 1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.
Trial: NCT05409326
Drug: TQH2722 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Trial: NCT05409326
Drug: Placebo to match TQH2722
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Trial: NCT06119685
Drug: IDP-023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK cell therapy
Trial: NCT06119685
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting chemotherapy
Trial: NCT04872257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally daily for 6 months
Trial: NCT04920149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IMP will be supplied as sachets with slow-releasing granules.